Wells Fargo & Company Exelixis, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Exelixis, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 68,224 shares of EXEL stock, worth $1.72 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
68,224
Previous 94,410
27.74%
Holding current value
$1.72 Million
Previous $2.24 Million
31.61%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding EXEL
# of Institutions
460Shares Held
240MCall Options Held
2.04MPut Options Held
1.29M-
Black Rock Inc. New York, NY33.5MShares$842 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.7MShares$746 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA27.1MShares$681 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.2MShares$381 Million0.6% of portfolio
-
State Street Corp Boston, MA12.6MShares$317 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $8.09B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...